Patents by Inventor Stanley J. Korsmeyer

Stanley J. Korsmeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BH3 peptides and methods of use thereof
    Patent number: 11225511
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: January 18, 2022
    Assignees: Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • Stabilized P53 peptides and uses thereof
    Patent number: 10202431
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: February 12, 2019
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Federico Bernal, Loren D. Walensky, Gregory L. Verdine, Stanley J. Korsmeyer
  • BH3 PEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20180244740
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Application
    Filed: January 12, 2018
    Publication date: August 30, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • BH3 peptides and methods of use thereof
    Patent number: 9902759
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: February 27, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • BH3 peptides and method of use thereof
    Patent number: 9856303
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: January 2, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • Stabilized P53 Peptides and Uses Thereof
    Publication number: 20170081379
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Application
    Filed: November 16, 2016
    Publication date: March 23, 2017
    Inventors: Federico BERNAL, Loren D. WALENSKY, Gregory L. VERDINE, Stanley J. KORSMEYER
  • Stabilized p53 peptides and uses thereof
    Patent number: 9527896
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: December 27, 2016
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Federico Bernal, Loren D. Walensky, Gregory L. Verdine, Stanley J. Korsmeyer
  • Stabilized alpha helical peptides and uses thereof
    Patent number: 9464115
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: October 11, 2016
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Loren D. Walensky, Stanley J. Korsmeyer, Gregory Verdine
  • BH3 PEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20160200786
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Application
    Filed: March 17, 2016
    Publication date: July 14, 2016
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • Stabilized alpha helical peptides and uses thereof
    Patent number: 9273099
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: March 1, 2016
    Assignees: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Loren D. Walensky, Stanley J. Korsmeyer, Susan Korsmeyer, Gregory Verdine
  • STABILIZED ALPHA HELICAL PEPTIDES AND USES THEREOF
    Publication number: 20140296160
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Application
    Filed: November 1, 2013
    Publication date: October 2, 2014
    Applicants: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Stanley J. Korsmeyer, Gregory Verdine
  • Stabilized alpha helical peptides and uses thereof
    Patent number: 8198405
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: June 12, 2012
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Loren D. Walensky, Stanley J. Korsmeyer, Susan Korsmeyer, legal representative, Gregory Verdine
  • STABILIZED ALPHA HELICAL PEPTIDES AND USES THEREOF
    Publication number: 20120082636
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Application
    Filed: October 4, 2011
    Publication date: April 5, 2012
    Inventors: Loren D. Walensky, Stanley J. Korsmeyer, Susan Korsmeyer, Gregory Verdine
  • BH3 Peptides And Method Of Use Thereof
    Publication number: 20110154522
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Application
    Filed: December 13, 2010
    Publication date: June 23, 2011
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • Inhibitors of Taspase1 protease activity
    Patent number: 7964700
    Abstract: A novel protease, Taspase1, is described. Taspase1 is involved in the cleavage of the myeloid/lymphoid or mixed-lineage leukemia (i.e., MLL) protein, which is required for proper HOX gene regulation. Diagnostic methods utilizing Taspase1 are provided, as well as inhibitors of Taspase1. Methods of using the inhibitors of Taspase1 are also described. For example an inhibitor of Taspase1 can be used to treat a cancer, e.g., leukemia, in a subject.
    Type: Grant
    Filed: September 6, 2007
    Date of Patent: June 21, 2011
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James J. D. Hsieh, Stanley J. Korsmeyer, Susan Korsmeyer, legal representative, Emily H. Y. Cheng
  • BH3 peptides and method of use thereof
    Patent number: 7868133
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: January 11, 2011
    Assignee: Dana Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • Method of treating apoptosis and compositions thereof
    Patent number: 7829662
    Abstract: Disclosed herein are novel polypeptides and the nucleic acid sequences that encode them. Also disclosed are antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. Vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same are also included. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders involving these novel human nucleic acids and proteins.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: November 9, 2010
    Assignee: Dana Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Luca Scorrano
  • METHODS OF MODULATING CELLULAR HOMEOSTATIC PATHWAYS AND CELLULAR SURVIVAL
    Publication number: 20100273704
    Abstract: The invention provides composition and therapeutic, methods for modulating homeostatic pathways that are useful in treatment, and prevention of diabetes, diabetes associated disorders, metabolic disorders and cancer.
    Type: Application
    Filed: May 2, 2008
    Publication date: October 28, 2010
    Inventors: Stanley J. Korsmeyer, Susan R. Korsmeyer, Nika N. Danial, Loren D. Walensky, Gregory Bird
  • STABILIZED P53 PEPTIDES AND USES THEREOF
    Publication number: 20100168388
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Application
    Filed: January 31, 2008
    Publication date: July 1, 2010
    Inventors: Federico Bernal, Loren D. Walensky, Gregory L. Verdine, Stanley J. Korsmeyer, Susan Korsmeyer
  • Stabilized alpha helical peptides and uses thereof
    Patent number: 7723469
    Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: May 25, 2010
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Stanley J. Korsmeyer, Susan Korsmeyer, legal representative, Gregory Verdine